bioengineer.org /3 weeks ago

Rare EGFR Mutation Shows Primary Resistance to Afatinib in Lung Cancer Case

A case report documents rapid progression and death in a lung cancer patient with a rare EGFR PACC mutation who showed primary resistance to afatinib.

Read source
bioengineer.org /1 month ago

Rare EGFR mutation sharply raises lung cancer risk in large genetic study

An observational study of 3.3 million research participants found that inherited EGFR T790M was associated with 25-fold higher lung cancer risk overall and more than 60-fold risk a...

Read source
bioengineer.org /1 week ago

Patient Survived Twenty Months After Small-Cell Transformation of Resected Lung Adenocarcinoma

A clinical case report documents a 48-year-old woman with EGFR-mutant lung adenocarcinoma who developed small-cell lung cancer transformation four years after surgery and survived...

Read source
journals.plos.org /3 days ago

GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

by Jingyi Ke, Zi Wang, Zhengyang Guo, Guangshuo Ou, Wei Li Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhib...

Read source
qchron.com /4 weeks ago

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-muta...

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G1...

Read source
qchron.com /4 weeks ago

RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-lin...

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...

Read source
qchron.com /3 weeks ago

Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy

Research Conducted at Tennessee Oncology's Greco-Hainsworth Centers for Research Contributes to Study Showing Longer Overall Survival with Next-Generation KRAS G12C Therapy

Read source
bioengineer.org /1 week ago

Meta-Analysis Assesses Targeted Therapies for MET-Altered Non-Small Cell Lung Cancer

A systematic review and meta-analysis of 25 clinical trials found that MET tyrosine kinase inhibitors achieved a 49 percent objective response rate in MET-altered non-small cell lu...

Read source
pharmexec.com /2 weeks ago

<![CDATA[FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer]]>

Read source
scmp.com /2 weeks ago

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in...

Read source
aacr.org /1 month ago

A New Way In: How Outside-the-box Science Sparked a Revolution in Targeting KRAS

At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize for his pioneering discoveries that opened the door to th...

Read source
aacr.org /2 weeks ago

Cracking “Undruggable” Cancer Proteins: Precision Oncology Meets p53

The development of KRAS inhibitors has ushered in a new era in precision oncology and renewed efforts in therapeutic targeting of p53, the most commonly altered gene in human cance...

Read source
qchron.com /4 weeks ago

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentati...

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P

Read source
qchron.com /2 weeks ago

Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibod...

Read source
qchron.com /4 weeks ago

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ES...

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89;...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.